Neurocrine公司抑郁症新药II期研究未达主要终点

GPLP犀牛财经
Nov 19, 2025

近日,神经科学领域的生物制药公司Neurocrine Biosciences宣布,在研抑郁症药物NBI-1070770的II期临床试验未能达到预设主要终点,这一结果也为其与武田制药的合作研发项目再添波折。据公开信息显示,NBI-1070770是一种选择性口服NMDA受体负变构调节剂,主要开发用于对至少一种抗抑郁药反应不足的成人重度抑郁症(MDD)患者,通过调节大脑关键蛋白发挥作用。该药物的研发权益...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10